Published in Drug Week, January 1st, 2010
One study, led by Robert C. Green, MD, MPH, of Boston University School of Medicine, shows that the drug tarenflurbil-which aims to suppress the accumulation of amyloid protein (plaque) in brain tissue-did not slow cognitive decline or loss of usual daily activities.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.